Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Gregory M. Weinhoff sold 10,000 shares of the business's stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $17.04, for a total value of $170,400.00. Following the completion of the sale, the insider now owns 183,266 shares of the company's stock, valued at $3,122,852.64. This trade represents a 5.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NASDAQ CNTA traded up $0.36 during mid-day trading on Thursday, reaching $17.26. The company's stock had a trading volume of 297,252 shares, compared to its average volume of 432,664. The stock has a fifty day moving average of $16.69 and a two-hundred day moving average of $13.78. Centessa Pharmaceuticals plc has a 52 week low of $6.65 and a 52 week high of $18.97. The firm has a market capitalization of $2.27 billion, a PE ratio of -11.28 and a beta of 1.52. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.05. As a group, sell-side analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.
A number of research firms recently issued reports on CNTA. B. Riley began coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a "buy" rating and a $33.00 price objective for the company. Guggenheim upped their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research report on Friday, November 15th. BMO Capital Markets lifted their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an "outperform" rating in a research note on Monday, September 16th. Jefferies Financial Group boosted their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. Finally, Morgan Stanley raised shares of Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $25.83.
Check Out Our Latest Stock Analysis on CNTA
Institutional investors and hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock worth $40,000 after acquiring an additional 826 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company's stock valued at $48,000 after acquiring an additional 1,509 shares during the last quarter. Quarry LP raised its position in Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company's stock valued at $87,000 after purchasing an additional 3,108 shares during the period. Sandia Investment Management LP purchased a new stake in shares of Centessa Pharmaceuticals in the 2nd quarter valued at approximately $90,000. Finally, Fred Alger Management LLC acquired a new position in Centessa Pharmaceuticals during the second quarter worth $99,000. Institutional investors and hedge funds own 82.01% of the company's stock.
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.